3 Top Biotech News Of The Week (6 August 22)
1) Beam served with clinical hold for Beam-201
$BEAM announced an FDA clinical hold on Beam-201, its multiplex silenced CD7 CAR-T asset. Beam-201 is an ex-vivo T-cell therapy being developed for relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic lymphoma.